TAGAMET PREVENT TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

CIMETIDINE

Inapatikana kutoka:

MEDTECH PRODUCTS INC

ATC kanuni:

A02BA01

INN (Jina la Kimataifa):

CIMETIDINE

Kipimo:

200MG

Dawa fomu:

TABLET

Tungo:

CIMETIDINE 200MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

100

Dawa ya aina:

OTC

Eneo la matibabu:

HISTAMINE H2-ANTAGONISTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0111925005; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2023-04-06

Tabia za bidhaa

_ _
_Page 1 of 24_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
TAGAMET® PREVENT
Cimetidine Tablets
Tablet, 200 mg, Oral
USP
Histamine H
2
– Receptor Antagonist
ATC Code: A02BA01
Medtech Products Inc.
660 White Plains Rd., Suite 250
Tarrytown, NY 10591
USA
Date of Initial Authorization:
Apr 12, 2000
Date of Revision:
Mar 22, 2023
Submission Control Number: 270508
_ _
_ _
_Page 2 of 24_
RECENT MAJOR LABEL CHANGES
None.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
....................................................... 5
4.5
Missed Dose
...........................................................................................................
5
5
OVERDOSAGE
................................................